Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies

Area of Science:

• Oncology
• Nanomedicine
• Immunology

Background:

• Osteosarcoma (OS) prognosis is poor, especially for unresectable or recurrent cases.
• While HER2 is overexpressed in most OS, anti-HER2 antibody trastuzumab (TRA) has shown limited benefit.
• HER2 expression in OS often lacks gene amplification, complicating targeted therapy based on breast cancer criteria.

Purpose of the Study:

• To review the rationale and mechanisms behind TRA/GO-mediated cytotoxicity in osteosarcoma.
• To explore the potential of TRA/GO complexes as a novel therapeutic strategy for osteosarcoma.
• To highlight necroptosis as a promising cancer cell death mechanism for chemo/apoptosis-resistant tumors.

Main Methods:

• Investigated the noncovalent association of trastuzumab (TRA) with graphene oxide (GO) to form TRA/GO complexes.
• Examined the mechanism of TRA/GO-induced cell death in osteosarcoma cells.
• Assessed the induction of oxidative stress, HER2 signaling, cIAP and caspase 8 degradation, and necroptosis activation.

Main Results:

• TRA/GO complexes rapidly kill osteosarcoma cells.
• TRA/GO induces oxidative stress and robust HER2 signaling, leading to cIAP and caspase 8 degradation.
• This process activates necroptosis, a potent form of programmed cell death.

Conclusions:

• TRA/GO complexes offer a novel therapeutic approach for osteosarcoma, bypassing resistance to conventional therapies.
• Necroptosis, induced by TRA/GO, presents an attractive cancer cell death mechanism due to its efficacy against resistant tumors and potential to enhance anti-tumor immunity.
• This strategy holds promise as a new class of anticancer therapeutics, distinct from existing treatments.